These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33026762)

  • 41. HAE update: determining optimal patient specific therapy.
    Gower RG
    Allergy Asthma Proc; 2013; 34(1):7-12. PubMed ID: 23406928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
    Banerji A; Davis KH; Brown TM; Hollis K; Hunter SM; Long J; Jain G; Devercelli G
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):600-607. PubMed ID: 32169514
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series.
    Hoarau C; Maleki A; Bouillet L; Boccon-Gibod I
    Orphanet J Rare Dis; 2024 Jul; 19(1):257. PubMed ID: 38978077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate.
    Tallroth GA
    Int Arch Allergy Immunol; 2011; 154(4):356-9. PubMed ID: 20975289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience.
    Abuzakouk M; Ghorab O; Al-Hameli H; Salvo F; Grandon D; Maurer M
    World Allergy Organ J; 2022 Jul; 15(7):100664. PubMed ID: 35891672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management and prevention of hereditary angioedema attacks.
    Lumry WR
    Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
    Lumry WR; Weller K; Magerl M; Banerji A; Longhurst HJ; Riedl MA; Lewis HB; Lu P; Devercelli G; Jain G; Maurer M;
    Allergy; 2021 Apr; 76(4):1188-1198. PubMed ID: 33258114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current and emerging therapies to prevent hereditary angioedema attacks.
    Lumry WR
    Am J Manag Care; 2018 Aug; 24(14 Suppl):S299-S307. PubMed ID: 30132644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
    Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
    Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.
    Valerieva A; Caccia S; Cicardi M
    Expert Rev Clin Immunol; 2018 Sep; 14(9):707-718. PubMed ID: 30021471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema.
    Lumry WR; Maurer M; Weller K; Riedl MA; Watt M; Yu M; Devercelli G; Meunier J; Banerji A;
    Ann Allergy Asthma Immunol; 2023 Jul; 131(1):101-108.e3. PubMed ID: 37028510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.
    Kreuz W; Martinez-Saguer I; Aygören-Pürsün E; Rusicke E; Heller C; Klingebiel T
    Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.
    Petkova E; Yordanova V; Staevska M; Valerieva A
    Drug Healthc Patient Saf; 2022; 14():195-210. PubMed ID: 36578774
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.
    Craig T; Zuraw B; Longhurst H; Cicardi M; Bork K; Grattan C; Katelaris C; Sussman G; Keith PK; Yang W; Hébert J; Hanzlikova J; Staubach-Renz P; Martinez-Saguer I; Magerl M; Aygören-Pürsün E; Farkas H; Reshef A; Kivity S; Neri S; Crisan I; Caballero T; Baeza ML; Hernandez MD; Li H; Lumry W; Bernstein JA; Hussain I; Anderson J; Schwartz LB; Jacobs J; Manning M; Levy D; Riedl M; Christiansen S; Feuersenger H; Pragst I; Mycroft S; Pawaskar D; Jacobs I;
    J Allergy Clin Immunol Pract; 2019; 7(6):1793-1802.e2. PubMed ID: 30772477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.
    Andrási N; Veszeli N; Holdonner Á; Temesszentandrási G; Kőhalmi KV; Varga L; Farkas H
    Int Immunopharmacol; 2020 Mar; 80():106216. PubMed ID: 31982824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
    Manning ME; Kashkin JM
    Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
    [No Abstract]   [Full Text] [Related]  

  • 59. Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.
    Pawaskar D; Tortorici MA; Zuraw B; Craig T; Cicardi M; Longhurst H; Li HH; Lumry WR; Martinez-Saguer I; Jacobs J; Bernstein JA; Riedl MA; Katelaris CH; Keith PK; Feussner A; Sidhu J
    Clin Exp Allergy; 2018 Oct; 48(10):1325-1332. PubMed ID: 29998524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
    Fain O; Du-Thanh A; Gobert D; Launay D; Inhaber N; Boudjemia K; Aubineau M; Sobel A; Boccon-Gibod I; Weiss L; Bouillet L
    Allergy Asthma Clin Immunol; 2022 Apr; 18(1):30. PubMed ID: 35365234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.